KR20210005070A - 갈랙틴-10 항체 - Google Patents

갈랙틴-10 항체 Download PDF

Info

Publication number
KR20210005070A
KR20210005070A KR1020207032847A KR20207032847A KR20210005070A KR 20210005070 A KR20210005070 A KR 20210005070A KR 1020207032847 A KR1020207032847 A KR 1020207032847A KR 20207032847 A KR20207032847 A KR 20207032847A KR 20210005070 A KR20210005070 A KR 20210005070A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
antagonist
galectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207032847A
Other languages
English (en)
Korean (ko)
Inventor
바트 램브레트
사바스 사비데스
하미다 하마드
케네스 베르스트라테
장-미쉘 페르시에
크리스토프 블랑쉬토트
미카엘 손더스
한스 데 하드
바스 반 데르 오닝
엠마 페르손
Original Assignee
아르제넥스 비브이비에이
유니베어지테트 헨트
브이아이비 브이지더블유
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1806099.6A external-priority patent/GB201806099D0/en
Priority claimed from GBGB1901648.4A external-priority patent/GB201901648D0/en
Application filed by 아르제넥스 비브이비에이, 유니베어지테트 헨트, 브이아이비 브이지더블유 filed Critical 아르제넥스 비브이비에이
Publication of KR20210005070A publication Critical patent/KR20210005070A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020207032847A 2018-04-13 2019-04-12 갈랙틴-10 항체 Ceased KR20210005070A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1806099.6A GB201806099D0 (en) 2018-04-13 2018-04-13 Galectin-10 Antibodies
GB1806099.6 2018-04-13
GBGB1901648.4A GB201901648D0 (en) 2019-02-06 2019-02-06 Galectin-10 antibodies
GB1901648.4 2019-02-06
PCT/EP2019/059570 WO2019197675A1 (en) 2018-04-13 2019-04-12 Galectin-10 antibodies

Publications (1)

Publication Number Publication Date
KR20210005070A true KR20210005070A (ko) 2021-01-13

Family

ID=66240109

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207032847A Ceased KR20210005070A (ko) 2018-04-13 2019-04-12 갈랙틴-10 항체

Country Status (12)

Country Link
US (3) US11066473B2 (https=)
EP (1) EP3774905A1 (https=)
JP (1) JP2021520825A (https=)
KR (1) KR20210005070A (https=)
CN (1) CN112166126A (https=)
AU (1) AU2019250689A1 (https=)
BR (1) BR112020020868A2 (https=)
CA (1) CA3094215A1 (https=)
IL (1) IL278010A (https=)
MX (1) MX2020010821A (https=)
SG (1) SG11202009140SA (https=)
WO (1) WO2019197675A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.
US11860114B2 (en) * 2020-03-26 2024-01-02 David Hurwitz Determining atomic coordinates from X-ray diffraction data
WO2021223079A1 (zh) * 2020-05-06 2021-11-11 科稷达隆(北京)生物技术有限公司 一种纳米抗体及其应用
CN113666999B (zh) * 2021-08-31 2022-08-19 中国医学科学院基础医学研究所 用于治疗2型免疫疾病的多肽
CN113667000B (zh) * 2021-08-31 2022-08-19 中国医学科学院基础医学研究所 多肽在制备治疗2型免疫疾病的药物中的应用
CN113999287B (zh) * 2021-12-02 2023-06-27 深圳湾实验室坪山生物医药研发转化中心 一种靶向半乳糖凝集素-10的多肽抑制剂及其制备方法和用途
IL314367A (en) 2022-01-18 2024-09-01 argenx BV Antibodies to galectin 10
KR20240133723A (ko) 2022-01-18 2024-09-04 아르제넥스 비브이 Fab 단편의 분무화
WO2023150260A2 (en) * 2022-02-03 2023-08-10 Regents Of The University Of Minnesota Compounds that target tem8, compositions, and methods
JPWO2023153496A1 (https=) * 2022-02-10 2023-08-17
CN115785245A (zh) * 2022-07-18 2023-03-14 上海博满生物科技有限公司 一种半乳糖凝集素10晶体及其制备的抗体IgY和药物制剂
CN115902204A (zh) * 2022-09-23 2023-04-04 北京大学第三医院（北京大学第三临床医学院） 一种外泌体形式半乳糖凝集素9的检测方法与试剂盒
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE10333406A1 (de) * 2003-07-15 2005-02-10 Protagen Ag T-regulatorische-Zellen enthaltend Galectine zur Therapie und Diagnose von Erkrankungen
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
CN106645752B (zh) * 2016-12-27 2018-02-16 中南大学湘雅医院 Galectin‑10及其特异性抗体在制备检测鼻咽癌试剂盒中的应用
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Also Published As

Publication number Publication date
SG11202009140SA (en) 2020-10-29
EP3774905A1 (en) 2021-02-17
JP2021520825A (ja) 2021-08-26
WO2019197675A1 (en) 2019-10-17
CA3094215A1 (en) 2019-10-17
MX2020010821A (es) 2021-01-15
US11713354B2 (en) 2023-08-01
US20240026010A1 (en) 2024-01-25
CN112166126A (zh) 2021-01-01
US11066473B2 (en) 2021-07-20
US20190367619A1 (en) 2019-12-05
BR112020020868A2 (pt) 2021-04-06
US20210332140A1 (en) 2021-10-28
AU2019250689A1 (en) 2020-10-08
IL278010A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
US11713354B2 (en) Galectin-10 antibodies
JP6345800B2 (ja) 抗体−フィノマー複合体
JP6250395B2 (ja) α２インテグリンに結合するペプチド又はペプチド複合体並びにそれに関与する方法及び使用
AU2018382527B2 (en) Anti-alpha synuclein antibodies
KR20160131061A (ko) 항-mcam 항체 및 관련된 사용 방법
CN106794129A (zh) 对il‑21具有特异性的结合分子及其用途
EP4331603A1 (en) Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof
US20230391869A1 (en) Inhibition of platelet aggregation using anti-human gpvi antibodies
CN115697393A (zh) 抗PHF-tau抗体及其用途
JP7080352B2 (ja) 糖タンパク質ｖｉを標的とする抗体
US20240067758A1 (en) Multi-specific antibodies and antibody combinations
TW202229337A (zh) 犬抗體變異體
KR20250023381A (ko) C-kit 및/또는 시글렉을 표적화하는 항체 및 이의 용도
KR20240133711A (ko) 갈랙틴-10 항체
JP2024532540A (ja) 二機能性融合タンパク質およびその用途
KR20230087552A (ko) Cd45를 다량체화하는 결합 분자
HK40034251A (en) Galectin-10 antibodies
JP7603061B2 (ja) Ｃｒ２結合タンパク質および医学的治療におけるそれらの使用
EA047651B1 (ru) Антитела против галектина-10
JP2017057201A (ja) 抗体−フィノマー複合体を含む医薬組成物
BR122024025202A2 (pt) Anticorpos multiespecíficos, polinucleotídeo isolado, vetor de expressão, célula hospedeira, método para produzir anticorpos multiespecíficos, composição farmacêutica e uso
CN121358778A (zh) Lilrb2结合蛋白及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201113

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20210525

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220407

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240919

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D